1. Suputtitada A. Spasticity : Physiology of normal muscle and pathophysioloy of spasticity.J Thai Rehabil 1999;8(3):230-40.
2. Nathan P. Some comments on spasticity and rigidity. In : Desmedt JE,ed. New developments in electromyography and clinical neurophysiology. Basel:Karga,
3. Lance JW. Pyramidal and extrapyramidal disorders.In: Shahani DT,ed. Electromyography in CNS disorders. Boston:Butterworth,1984:1-19. 
4. Mayer NH. Clinicophysiologic concepts of spsticity and motor dysfunction in
adults with an upper motoneuron lesion. Muscle Nerve1997;20(suppl 6) :S1-S13.
5. Hoefer PFA, Putnam TJ. Action potentials of muscles in spastic conditions Arch
Neurol Psychiat  1940;43:1-22.
6. Mayer N. Esquenazi A, Childrens MK. Common pattern of clinical motor
dysfunction. Muscle Nerve 1997; 20 ( suppl 6 ) : S21-S35.
7. Esquenazi A, Mayer N. New advances in the management of spasticity& muscle overactivity. CD-ROM by Professional Postgraduate Services, a division of
Physicians World Communication Group. May 2000
8. Little JW, Massagi TL. Spasticity and associated abnormalities of muscle tone.
In: Delisa  JA, ed. Rehabilitation medicine : principle and practice. 2nd ed.
Philadephia : JB lippincott, 1993 : 668-76.
9. Suputtitada A. New techniques in the treatment of spasticity. Chula Med J 1999;
10. Gormley MF,O'Brien CF, Yablon SA. A clinical overview of treatment decisions in
the management of  spasticity. Muscle Nerve 1997;20(suppl 6):S14-S20.
11. Little JW, Merritt JL. Spasticity and associated abnormalities of muscle tone.In
:Delisa JA, ed. Rehabilitation Medicine : Principles and Practice. Philadelphia
:Lippincott, 1988 ; 565-84.
12. Keeman MAE, Eufrocina ST, Stone L, Gersten LM. Percutaneous phenol block
of the musculocutaneous nerve to control elbow flexor spasticity. J Hand Surg
1990 ; 15A (2) : 340 -46.
13. Young RR. Physiologic and pharmacologic approaches to spasticity . Neurologic clinics 1987 ; 5 (4) : 529-39.
14. Award EA, Dykstra D. Treatment of spasticity by neurolysis. In: Kottke FJ, Stillwell
GK, Lehmann JF,eds. Krusen's Handbook of Physical Medicine and
Rehabilitation. 4 th ed. Philadelphia; WB Saunder,1990 : 1154-61.
15. Brin MF. Botulinum toxin: Chenistry, Pharmacology, Toxicity, and Immunology.
Muscle Nerve 1997;20(Suppl 6): S146-167.
16. Das TK, Park DM. Botulinum toxin in treating spasticity. By J Clin Pharmacol
1989 ; 43 : 401-3.
17. Hesse S, Friedrich H, Domasch C,  Mauritz KH. Botulinum toxin therapy for
upper limb flexor spasticity : preliminary results. J of Rehabil Sci 1992
18. Koman LA, Mooney JF, Smith B,et al. Management of cerebral palsy with botulinum A toxin : Preliminary investigation. J Ped orthopedics 1993; 13:
19. Cosgrove AP, Graham HK. Botulinum toxin A in the management of children with
cerebral palsy . Bone and joint Surg (BR). 1992;74-B ( Suppl II) L 135-6
20. Calderon-gongalez R, Calderon- sepulveda R F. Patho physiology of spasticity and the role of botulinum toxin in its treatment . Acta Neuropediatr 1994; 44-57
21. Snow BJ, Tsui JKC, Bhatt MH,et al. Treatment of spasticity with botulinum toxin :  A double-bind study. Ann Neurol 1990; 28:512-5.
22. Hesse S, Lucke D, Malezic al. Botulinum toxin treatment for lower limb extensor spasticity in chronic hemiparetic patients. J Neurol Neurosurg Psychiat
23. Viriyavejakul A, Vachalathiti R, Poungvarin N. Botulinum treatment for post-stroke Spasticity : Low dose regime. J Med Assoc Thai 1998;81(6):413-22.
24. Suputtitada A. Managing Spasticity in Pediatric Cerebral Palsy Using a Very Low
Dose of Botulinum Toxin Type A; Preliminary Report .Am J Phy Med Rehabil
25. Suputtitada A. Local botulinum toxin injection in the treatment of spastic toes.
Abstract. The 6th International Congress of Parkinson's disease and Movement
Disorders, Barcelona, Spain, 11-15 June 2000
26. Nathan PW. Chemical rhizotomy for relieve of spasticity in ambulant patients. Br
Med J 1965;1(5442):1096-100.
27. Putnam TJ, Hampton AO. A  Technique of injection in the gasserian ganglion
under roentgenographic control. Arch Neurol Psychiat 1936 ; 35(1):92-8.
28. Tamura K. Histopathological studies of the spinal cord following subarachnoid
block using phenol,clinical and experimental studies. Masui Jpn J Anesthesiol
1975; 24(7): 681-94.
29. Khalili AA, Harmel MN, Forster S, Benton JG. Management of spasticity by
selective peripheral nerve block with dilute phenol solutions in clinical
rehabilitation. Arch Phys  Med Rehabil 1964;45(10):513-9.
30. Khalili AA,Betts HB. Peripheral nerve block with phenol in the management of
spasticity: Indication and complications. JAMA 1967;48(2):97-9.
31. Garland DE,Lilling M, Keenan MA. Percutaneous phenol blocks to motor points
of spastic forearm muscles in head-injured adults. Arch Phys Med Rehabil
32. Keenan MA, Botte MJ. Technique of percutaneous phenol block of the recurrent
motor branch of the median nerve. J Hand Surg(Am)1987;12A(5):806-7.
33. Garland DE,Lucie RS, Waters RL. Current uses of open phenol nerve block for
adult acquired spasticity. Clin Orthop 1982;165:217-22.
34. Botte MJ, Keenan MA. Brain injury and stroke. In: Gelberman RH,ed. Operative
nerve repair and reconstruction. Philadelphia: JB Lippincott,1991:1415-51.
35. Botte MJ, Abrams RA, Bodine-Fowler SC. Treatment of acquired muscle
spasticity using phenol peripheral nerve blocks.Orthopaedics 1995;18(2):151-9.
36. Halpern D, Meelhuysen FE. Phenol motor point block in the management of
muscular hypertonia.Arch Phys Med Rehabil 1966;47(10):659-64.
37. Halpern D, Meelhuysen FE. Duration of relaxation after intramuscular neurolysis
with phenol. JAMA 1967;200(13):1152-4.
38. Khalili AA, Benton JG. A physiologic approach to the evaluation and the
treatment of spasticity with procaine and phenol nerve block: including a review
of the physiology of the stretch reflex. Clin Orthop 1966;47:97-104.
39. Botte MJ, Keenan MA. Percutaneous phenol blocks of the pectoralis major
muscle to treat Spastic deformities. J Hand Surg (AM)1988;13A(1):147-9.
40. Khunphasee A, Aimprasitichai S, Intharakumhang P, Phatharawarathum S,
Theranathara K, Tosayanonda O, Khunadorn F. Phenol block in spasticity.
J Thai Rehabil 1991;1(2):15-8.
41. Calderon-gonzalez R, Calderon sepulveda RF. Pathophysiology of  spasticity
and the role of botulinum toxin in its treatment. Acta Neuropediatrica
42. Shaari CM, George E, Wu BL, Biller HF, Sanders I. Quantifying the spread of
botulinum toxin through muscle fascia. Larynogoscope 1991;101:960-4.
43. Lange DJ, brin MF, Warner CL, Fahn S, lovelace RE. Distant effects of local
injection of botulinum toxin. Muscle and Nerve 1987;10:552-5.
44. Sanders DB, Massey EW, Buckley EG. Botulinum toxin for blepharospasm :
single-fiber EMG studies. Neurology 1986;36:545-7.
45. Khunphasee A, Khunadorn F. Treatment of spasticity by phenol intramuscular
neurolysis at Pramongkutklao Hospital. J Thai Rehabil 1998;7(3): 108-114.
46. Suputtitada A . Symposium of Botulinum toxin A : Update clinical application in
dystonia And spasticity. Medical Time 2000;2(28):S1-S4.
47. Gracies JM, Elovic E, McGuire J, Simpson DM. Traditional pharmacological
tratments for spasticity  Part I : Local treatments. Muscle Nerve 1997;20
(suppl 6):S61-S91.
48. Boyd RN,Graham JEA, Nattrass GR, Graham HK.  Medium-term response
characterization and risk  factor analysis of botulinum toxin type A in the
management of spasticity in children with cerebral  palsy. Eur J Neurol
1999;6(suppl 4) : S37-45.